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Abstract:  Leukemia is the number one cancer affecting children in the nation, with acute 
lymphoblastic leukemia being the most prevalent classification.1 While new and innovative 
treatment protocols have greatly increased the success rate of primary cancer patients, those who 
face relapse receive a much more dismal prognosis. Recent studies have shown that patients who 
relapse quite frequently have developed drug-resistant clones of the original cancer cells, leading 
to a need for various secondary treatment options. The drug-resistance is due to clonal mutations 
that take place within the cancer cell, most often because of an outside pressure or stress within 
the environment of the cell. In fact, studies show that in many cases the chemotherapy and 
radiation treatment administered to the leukemia patients provides the added pressures necessary 
to promote these clonal mutations, leading to treatment-resistant cells and the onset of relapsed 
leukemia. Various immunotherapies are becoming the front-line secondary treatment option due 
to their high success rates and innovative techniques. Monoclonal antibodies such as 
Blinatumomab or Inatuzumab are currently the primary targets of research for acute 
lymphoblastic leukemia secondary therapy. However, dual therapy treatments of cancers have 
shown increased rates of event-free survival, overall survival, and progression-free survival, as 
well as decreased rates of drug resistant cancer cells. Therefore, the goal of this review is to 
promote the application of dual treatment therapy on relapsed ALL cells for improved outcome, 
as well as on primary ALL cells for decreased drug resistance.  
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DUAL THERAPY TREATMENT OF PEDIATRIC ACUTE LYMPHOBLASTIC LEUKEMIA 




Imagine that you are working to solve an incredibly complex problem, one that takes you 
years of hard work, and then finally after multiple heart-wrenching failures you determine a 
possible route that shows promising leads to an answer.  Then, when you at last feel like a 
solution is within reach, a new variable is thrown into the problem that introduces a completely 
unforeseen challenge in reaching your end goal.  This is oftentimes exactly what the frustrating 
battle with cancer can feel like.   
There is an abundant selection of promising therapies and treatments for many common 
cancers and malignancies, but unfortunately, many of them still result in the cancer returning 
with a new set of mutated genes that are prepared to fight even harder than before.  Rare cancers 
as well face many difficult obstacles to overcome when formulating a treatment plan.  It can be a 
disheartening battle when treatment initially rids the body of malignant cells, but then new 
cancerous cells develop that are specifically made to resist the treatment that was once so 
promising.1-3  This is why one of the greatest gifts that can be given to patients with these 
devastating afflictions is time.  However, with many advances in technology today, there is 
potential to outsmart the cancer cells before they have the opportunity to mutate and deceive the 
body.  With the implementation of dual-therapy treatments in many varieties of cancer, survival 
rates have significantly increased.3  There have also been noticeable decreases in rates of 
relapse3, which is one of the key indicators measured when analyzing overall survival for cancer 
patients.  If there was an opportunity for a treatment that not only aided a patient’s immune 




measures should be taken, and all costs be funded in order to achieve this goal.  The capability of 
a treatment to increase the patient’s quality of life and life expectancy should be a primary goal 
in cancer research.  Presented within this thesis is a proposal to combine a standard 
chemotherapy regimen, which has been shown to limit cancer cell growth and expansion, with an 
innovative monoclonal antibody named Blinatumomab to directly target the patient’s immune 
response cells to initiate the desired apoptotic effect on cancerous acute lymphoblastic leukemia 
cells.  Blinatumomab is considered an immunotherapeutic agent because of its ability to 
empower the patient’s own immune system to defeat the cancer cells.  It has shown great 
promise in previous studies with acute lymphoblastic leukemia patients, and in combination with 
chemotherapy could be a lifechanging treatment for these children.1,2  In order to accurately 
determine the potential for a dual therapy treatment to effectively treat relapsed leukemia 
patients, as well as to decrease rates of relapse in primary cancer diagnosed patients, several tests 
should be completed.  The goals of each test are to examine the efficacy of a dual therapy 
treatment in comparison to a monotherapy treatment for both primary and secondary leukemia, 
as well as to research a potential treatment for a population of cancer patients that do not contain 
the receptor that Blinatumomab targets.  If the tests give promising results, then the next goal 














Background and Significance 
 
Leukemia, a well-known disease affecting the blood cells, is the number one cancer in the 
pediatric population, and the second cause of death in children age’s 0-14.3  There are four 
classifications of leukemia including Chronic Myeloid, Chronic Lymphoblastic, Acute Myeloid, 
and Acute Lymphoblastic.  The most prevalent form in children is Acute Lymphoblastic 
Leukemia (ALL), which is diagnosed in approximately 3,800 patients each year, comprising 
nearly eighty percent of all ALL cases diagnosed annually.4,5  Since the discovery of leukemia in 
the 19th century, the methods of treatment for this significant number of patients have improved 
considerably, leading to a substantial increase in patient overall survival rates.3 
 In 1847 the disease was named by Dr. Rudolf Virchow, a German politician who spent a 
large part of his time researching cell biology, pathology and anthropology.6  However, the first 
published case of the disease was in 1899 when Major Samuel T. Armstrong, a military surgeon, 
died of the disease in Manila.6  By 1913 there had been several more case reports of deaths 
caused by leukemia, as well as the discovery of the different classifications of the disease.  The 
first mention of treatment was in December of 1913, when physicians attempted to treat a student 
from Cornell University by performing a blood transfusion with his twin brother, which was 
unsuccessful.6  Two years later, doctors discovered that radium was successful in treating 
patients, but the poison had severe negative effects on the body systems.  However, radiation 
therapy is still a widely used treatment for the cancer today.  By the 1930’s the disease had been 
frequently mentioned, but was still left without a cure, other than futile attempts at blood 
transfusions.  In 1946 the treatment of leukemia with chemicals was first mentioned in The New 
York Times after an anonymous reporter shared that chemical medications rejected for the 




leukemia therapies.6  Today, there is still no defined cure for leukemia, but treatments such as 
chemotherapy, stem cell transplants, and new immunotherapies have significantly increased the 
survival rate of diagnosed patients.3 
The cause of leukemia varies from patient to patient, but like any cancer there are various 
factors that can increase the likelihood of developing the disease.  Recent studies have shown 
that multiple genetic syndromes can predispose a patient to developing ALL, including Down 
syndrome, Fanconi anemia, Bloom syndrome, ataxia telangiectasia, and Nijmegen breakdown 
syndrome.5  Other predisposing factors include exposure to pesticides, ionizing radiation, or 
certain viruses such as Epstein-Barr Virus or Human Immunodeficiency Virus.5  However, in the 
majority of diagnoses the disease develops de novo in previously healthy individuals.  ALL can 
be further divided into two main classifications, namely, B cell ALL and T cell ALL.  Seventy-
five to eighty-five percent of all pediatric patients with ALL have cancer cells that developed 
from the B cell origin, leading to the arrest of an immature B cell progenitor.7  B-ALL typically 
develops in utero as a result of a chromosomal translocation, of which there are many 
variations.7  This abnormality causes a differentiation arrest in developing B lymphoid cells, 
leading to their suspension in a differentiated state before having reached maturity, or in some 
cases they are reverted to a pre-differentiation state and then arrested, causing them to rapidly 
proliferate as leukemia blasts.8,9  The leukemia blasts will then advance from the bone marrow 
into the bloodstream to penetrate the spleen, liver, central nervous system, thymus and lymph 
nodes.2  This takeover of the hematopoietic system also has detrimental effects on red blood cells 
and platelets by significantly decreasing their counts within the peripheral blood.8  The negative 
effects on the hematopoietic system then have further consequences on other body systems such 




genetic abnormalities leading to the occurrence of acute lymphoblastic leukemia, including the 
formation of the Philadelphia chromosome (see Figure 1).  This is typically cause by the 
chromosomal fusion of the BCR and ABL genes from chromosomes 9 and 22, producing a 
significantly shorter chromosome as well as significant health defects.10  This fusion leads to the 
activation of downstream kinases within multiple signaling pathways which causes cells to stray 
from their normal signal response, thereby causing proliferation and oncogenesis of leukemia, 
many times being initiated in the myeloid compartment.11  The myeloid compartment is a part of 
the immune system and contains a large mixed group of myeloid-stemmed cells including 
neutrophils, eosinophils, dendritic cells, and mast cells.12  The problem with the interaction of the 
myeloid compartment with the Philadelphia chromosome is that all of cells contained within this 
section can be affected by the Philadelphia mutation, thereby causing a greater distribution 
throughout the body.13 The myeloid cells within the myeloid compartment, when influenced by 
cancerous cells, play a large role in the metastatic process of cancer development, from 
delamination from the primary tumor mass to the invasion of neighboring tissue to eventual 
colonization of the site of metastasis.12  However, in many cases the genetic alterations are not 
enough to cause the onset of the disease, and therefore a second factor is required.  Potential 
secondary contributors to leukemia are currently being studied and include environmental, 
ethnic, immunologic, infectious, and socioeconomic components.7 
Treatment of acute lymphoblastic leukemia has greatly improved over the years with the 
advent of multidrug, risk-adapted chemotherapy regimens, as well as recognition of treatment 
response characteristics that can identify patients at risk for treatment failure.14  This has led to 
cure rates of approximately 90%, an astounding statistic, however for the 10-20% of pediatric 




twenty years.15  Current treatment for relapsed ALL is surprisingly similar to primarily 
diagnosed patients with the exception that treatment is typically dose intensified or given on 
alternative schedules.14  Once a patient reaches second complete remission (CR2) they will 
usually continue intensive chemotherapy treatment.  Furthermore, a hematopoietic stem cell 
transplant is also a potential treatment for the secondary cancer.  However, these treatment 
strategies have not led to significantly improved overall survival (OS) rates, especially with 
relapsed cancers with poor prognostic factors such as early bone marrow relapse, thereby leading 
to the need for novel treatment therapies.14   
Currently the best primary treatment for patients originally diagnosed with ALL is a 
regimen of chemotherapy with the goal of reaching induction, followed by consolidation and 
then maintenance therapy.14  The best indicator of long-term survival is the quantity of time a 
patient survives disease-free.16  Patients that relapse within one year of being declared disease-
free maintain the most dismal prognosis of long-term survival.17  Therefore, it is vital to 
implement treatment options that decreased rates of relapse within patients to give them a great 
chance at long-term survival. 
 
Primary Treatment Options 
 With the increasing percentage of annual leukemia diagnoses in the United States, a 
standard treatment protocol for the cancer is required.  Typically, when a patient is initially 
diagnosed with acute lymphoblastic leukemia, they will undergo a three-phase cancer treatment 
process as mentioned above.  These three steps include induction (or remission induction), 
consolidation (or intensification), and then maintenance therapy.18  The goal of the induction 




tissue samples, normal marrow cells return, and the blood counts become normalized.18  This 
does not mean, however, that the patient is “cured”,  because there may still be remnant cancer 
cells undetected within the patient’s body.  Typical chemotherapy drugs administered during the 
induction phase include Vincristine, Dexamethasone or prednisone, or Doxorubicin.18  
Doxorubicin is an anthracycline antibiotic administered intravenously through either a central or 
peripheral venous line.19  Furthermore, Doxorubicin is also a vesicant, meaning that it can cause 
severe tissue damage if it escapes from the vein.19  Doxorubicin is an antitumor antibiotic, 
meaning that it is derived from a natural product and acts during multiple phases of the cell-
cycle, thereby making it a cell-cycle specific drug.19  Chemotherapy drugs such as Doxorubicin 
are not cancer specific and can target any rapidly dividing cell, leading to common side effects 
such as hair loss (alopecia), mouth sores, nausea, and diarrhea.19  Dexamethasone is a second 
chemotherapeutic drug commonly used for treatment of ALL.  It is a glucocorticosteroid that is 
distributed in pill form, many times alongside other chemotherapy drugs.20  It is an anti-
inflammatory frequently used in the short-term treatment of nausea caused by other 
chemotherapy drugs, but it has also been found to cause apoptosis, and can therefore aid in the 
fight against the cancerous cells.20  Finally, Vincristine is a third drug commonly used in 
treatment for ALL among other cancers.21  It is also a vesicant that is given intravenously, and 
risks the same side effects as Doxorubicin.21  Furthermore, it belongs to a class of chemotherapy 
drugs called plant alkaloids, and is specifically a member of the vinca alkaloids group.  Vinca 
alkaloids are microtubule agents that inhibit the microtubule structures within a cell, preventing 
proper division and replication, and eventually leading to cell death.21  However, chemotherapy 




incredibly beneficial to propose treatment options that minimize use of vesicant chemotherapies, 
or eliminate them completely. 
Incidence of Relapse 
 While current treatment therapies for acute lymphoblastic leukemia have led to the 
astonishing survival of 90% of patients, the prognosis for the 10-20% that face relapse is 
oftentimes discouraging.2  Chromosomal abnormalities, genetic mutations, and decreased 
responsiveness to chemotherapy are but a few of the differences seen between primarily 
diagnosed leukemia and the relapsed cancer.22  A study done by Mullighan et al.22 researched the 
genetic basis of relapse by performing DNA copy number analyses on both diagnosis and relapse 
samples from acute lymphoblastic leukemia patients.  The results showed a majority of patients 
had different copy number abnormalities (CNAs) between relapse and diagnosis, specifically 
relapse samples lacked some of the CNAs identified at diagnosis, leading to the conclusion that 
genetic anomalies that lead to ALL relapse are brought about during therapeutic treatment and 
that the signaling pathways affected by these modifications may be promising targets for 
intervention.22  Furthermore, a study done by Greaves et al. also showed how therapeutic 
treatment may inadvertently cause resistant variations in the cancer cells to evolve while the 
original clonal cells are being exterminated.23  Studying matched pair samples from the same 
patient has allowed for observation of the biological pathways responsible for the drug resistant 
phenotype seen at relapse.24,25  Copy number analyses (CNA) were performed by various 
researchers to detect copy number variations (CNVs), which are genomic alterations leading to 
an abnormal number of copies of one or more genes, due to either deletions, duplications, 
translocations or inversions.26  Previous studies have shown that there are distinct genetic 




samples by CNA has also provided the opportunity to study the clonal evolution over time and 
map its origin.24  In fact, studies show that the vast majority (approximately 94%) of relapses are 
derived from a clone present at diagnosis, while a small minority (close to 6%) occur from a 
genetically new leukemia.14  Nearly 34% of these clones derived from the original cancer were 
present at diagnosis, while close to 52% evolved from the ancestral clone, as seen in Figure 2.14  
Furthermore, the CNA revealed that focal deletions were more common than additions, 
specifically deletions of IKZF1, EBF1, BTG1, TBL1XR1, and MSH6.14  IKZF1 is a gene 
responsible for encoding the lymphoid TF IKAROS, and deletion of this gene has been defined 
as a strong indicator of relapse.27  Other deletions such as NR3C1, BTG1, and TBL1XR1 have 
been identified in B-ALL as factors leading to glucocorticosteroid resistance.28  Along with 
genetic deletions present in mutations at relapse, there are also multiple signaling pathways that 
can develop genomic lesions, leading to resistance to nearly all drug therapies.  Studies done that 
performed integrated genomic profiling revealed that the activation of the WNT and MAPK 
pathways are frequently observed at relapse, and therefore could be a potential target for 
treatment.29   
Clonal evolution following therapeutic treatment is becoming an increasingly recognized 
topic to begin to study the effects of chemotherapy and radiation treatment on cancer cells, not 
just as eradicators of the clonal cells rapidly proliferating, but also as amplifiers of clonal 
mutations causing resistance to further therapeutic treatments.30,31 
 
Secondary Treatment Options 
Immunotherapy is arguably the most promising leukemia treatment currently being 




leukemic clones rather than merely administering exogenous chemicals to destroy the rapidly 
dividing cells.  Two of the most increasingly popular immunotherapy methods being studied are 
CAR-T cells and monoclonal antibodies.  Chimeric antigen receptor T cell (CAR-T cell) therapy 
works by engineering T lymphocytes from the patients’ blood with synthetic receptors made to 
recognize and eliminate specific cancer cells.32  T cells are initially collected from the peripheral 
blood by leukapheresis, followed by apheresis.  The separated T cells are then transfected with a 
viral or non-viral vector containing the CAR genome, and then expanded and purified.32  Finally, 
the cells are tested for quality and sterility, which is a process that takes approximately two to 
four weeks (see Figure 3)  Before the patient is injected with the resulting cells, they must 
undergo a lymphodepletion treatment.32 CAR-T cells have been found to be most beneficial in 
the treatment of hematological malignancies such as leukemias, lymphomas, and myelomas .  
They are also most effective as anti-CD19 receptors, due to the fact that CD19 is a cell marker 
characterized with high expression in B-ALL cells.32  A recent study done by Jae et al. analyzed 
the use of CAR-T cell therapy on fifty-three patients with relapsed B-ALL.33  Patients received 
an infusion of T-cells expressing 19-28z CARs, meaning that the chimeric receptor was 
composed of an anti-CD19 antibody binding site as well as intracellular domains from the T-cell 
coactivating receptors CD28 and CD3-zeta chain.33  The results showed that a total of 83% of 
patients reached complete remission (CR), with an overall survival of 12.9 months.33  The two 
most toxic side effects observed with CAR-T cell treatment were cytokine release syndrome 
(CRS) and neurotoxicity.33  
Blinatumomab is a monoclonal antibody (mAb) that has been reported as the most 
promising agent of innovative ALL treatment currently being studied.  It is a bispecific T cell 




CD19 is one of the most commonly expressed cell surface markers on cancerous lymphoblasts.  
The second arm of the Ab binds to healthy CD3+ T cells to facilitate the upregulation of T cell 
activation and increased cytotoxicity and apoptosis of the cancer cell.34  The mechanism through 
which Blinatumomab works can be seen in Figure 4.35  With the binding of each arm of the 
bispecific antibody, it allows for the juxtaposition of CD3+ T-cells to malignant B-cells, which 
leads to the production of granzymes and perforins, thereby initiating apoptosis.36  
One of the main consequences of treatment with both CAR-T cells and Blinatumomab is 
cytokine release syndrome (CRS).  Specifically, the increase in IL-6, IL-10, and IFN-γ.37  
Clinical manifestations of CRS include high fever, hypotension, hypoxia, and respiratory 
distress.38  Furthermore, organ dysfunctions can also occur, including liver transaminitis and 
renal insufficiency, as well as other life-threatening complications.38  However, Blinatumomab is 
known to have lower rates of CRS in comparison to CAR-T cell therapy.38  Due to the high 
increase in expression of IL-6 with CRS, inhibitors specifically for IL-6 have been studied and 
shown to dramatically improve effects of CRS.37,38  
Blinatumomab has recently been approved by the FDA for the treatment of acute 
lymphoblastic leukemia, and has shown increased rates of event-free survival, disease-free 
survival, and progression-free survival in comparison to standard chemotherapy treatment 
alone.39  However, dual therapy treatments have shown even greater results, especially 
monoclonal antibody and chemotherapy combination therapy.  Therefore, the dual therapy 
treatment of acute lymphoblastic leukemia with Blinatumomab and chemotherapy is a potential 






Dual Therapy Treatments 
Dual therapy treatment of various cancers is becoming a widely recognized and encouraged 
tactic for the battle against cancer.  While monotherapy regimens have shown promising results 
and are sufficient for the treatment of some patients, there are numerous limitations to response 
rates and duration of therapy.40  The goal of combination therapy is to make the target cells more 
immunogenic, thereby increasing the effects of the immunotherapy when given with other 
treatment regimens.  There are several methods by which immunotherapy makes a tumor cell 
more immunogenic.  The first is by increasing the antigen and MHC Class I expression on the 
cancer cell to increase likelihood of T-cells binding to the cell to initiate cell-mediated 
apoptosis.40  Another method is by altering the environment around the tumor cell by either 
increasing vascular permeability and T-cell secreted molecules that induce cell death, or by 
initiating a positive effect on cytotoxic T-cells within the tumor.40  As the result of many 
oncologic studies being performed, a key conclusion is that therapeutic resistance occurs much 
more commonly in single-agent therapy than with multi-drug therapy.40  Therefore, dual therapy 
would be a beneficial treatment for acute lymphoblastic leukemia by making leukemia cells 
more immunogenic while at the same time helping the cytotoxic cells of the immune system to 
engage these cells more efficiently, leading to an improved response and decreased likelihood of 
drug-resistant cells.   
Dual therapy regimens have shown very promising results in other cancer studies as well.  
For example, Pfreundschuh et al. aimed to explore the impact of CHOP (cyclophosphamide, 
doxorubicin, vincristine, and prednisone)-like chemotherapy regimens partnered with the 
monoclonal antibody rituximab for the treatment of large B-cell lymphoma.2  For their study, 




like chemotherapy and rituximab or six cycles of CHOP-like chemotherapy alone.  The main 
goal for all of the patients was event-free survival, with secondary goals of overall survival, 
progression-free survival, progression under therapy, and frequency of toxic effects.2  After the 
median follow-up of 34 months, patients who received the combined chemotherapy-rituximab 
therapy had increased three year event-free survival compared with the group who were assigned 
only chemotherapy.2  Before beginning treatment, the stage of lymphoma was defined by 
physical examination from a physician along with laboratory tests such as hemoglobin, platelets, 
total white blood cell count, differential WBC count, bone marrow biopsy, etc.  The size of the 
tumor mass was assessed by local physicians and a radiologist, and then the patients were 
assigned to their trial, either with or without rituximab.  The majority of countries participating 
in this trial had their patients undergo the CHOP-21 Regimen guidelines, which included 750 
mg/m2 cyclophosphamide, 50 mg/m2 doxorubicin, and 2 mg vincristine all given intravenously 
on days 1, 22, 443, 64, 85, and 106; and 100 mg of prednisone were given on days 1-5. 22-26, 
43-47, 64-68, 85-89, and 106-110.2  Those who were assigned to also receive rituximab followed 
this schedule, along with 375 mg/m2 rituximab administered intravenously on days 1, 22, 43, 64, 
85, and 106 of the CHOP regimen.2  Patients received follow-up appointments every three 
months for the first two years after treatment, and then every six months.  Their follow-ups 
included the same laboratory tests administered during staging, as well as physical examination 
performed by the physician, and a CT of the chest and abdomen.2  The results of which can be 
seen in Figure 5.2  Furthermore, the effect of rituximab was also examined specifically in young 
patients.  In fact, nearly twice as many (41% versus 21%) young good-prognosis patients failed 
after chemotherapy treatment alone rather than chemotherapy combined with rituximab.2  




event-free survival, progression-free survival, and overall survival.  Another study done by Sehn 
et al. came to the same conclusion that the addition of rituximab to CHOP-like chemotherapy 
resulted in significantly improved patient outcomes in the treatment of diffuse large B-cell 
lymphoma compared to chemotherapy treatment alone after studying a total of 292 patients.41  
In conclusion, dual therapy treatments with monoclonal antibodies and chemotherapy have 
shown highly beneficial treatment outcomes when compared to treatment with chemotherapy 
alone.  Furthermore, treatment of young patients (<20 years) also maintained the finding that the 
combined therapy led to increased overall survival, event-free survival, and progression-free 
survival.  Therefore, it would be worth the cost of adding Blinatumomab into the treatment 

















Clinical Presentation and Management 
Clinical Signs and Symptoms 
Being a cancer of the immune system, Acute Lymphoblastic Leukemia presents itself in 
many ways, some of them deceptive and misleading.  In fact, many symptoms mimic those of 
the flu, but while flu symptoms eventually improve, symptoms of ALL will persist and are clear 
indicators to make an appointment with a physician.42  Signs and symptoms may include bone 
pain, fever, frequent infections, pale skin, shortness of breath, weakness and fatigue, lumps 
caused by swollen lymph nodes in the neck, underarms, or groin, and possible bleeding from the 
gums.42  Many of these symptoms are a result of the rapid proliferation and accumulation of 
undifferentiated lymphoid cells within the bone marrow, peripheral blood, and extramedullary 
sites.43  Further symptoms such as anemia, thrombocytopenia, and leukopenia, all of which can 
be diagnosed through a physical exam and complete blood count test, can also constitute bone 
marrow failure within the disease.43  Accumulation of undifferentiated cells in extramedullary 
sites such as the lymph nodes, spleen, and liver can lead to organ enlargement in 20% of 
patients.44  Any of these signs and symptoms should be taken as a clear indicator to visit a 
physician.   
 
Diagnostic Tests and Tools 
Typically if acute lymphoblastic leukemia or any immune system disorder is suspected, a 
physician will order various tests to confirm.  First is a complete blood count (CBC), which   
measures the cell counts of several components and features of blood, including red blood cells 
(RBC’s), white blood cells (WBC’s), hemoglobin (Hgb), hematocrit, and platelets.45  Each 




insight into underlying medical conditions.  Following the CBC, if leukemia is still suspected, 
the physician can order a bone marrow test.  The bone marrow test consists of a bone marrow 
aspiration and/or biopsy.  During the aspiration, a needle is inserted most commonly into the 
posterior iliac crest to collect a sample of bone marrow fluid.46  If a bone marrow biopsy is also 
being performed, then a larger needle will be used to collect a sample of bone marrow tissue 
following the aspiration.  After the large needle is inserted into the bone, the center of the needle 
is removed and the hollow needle moved deeper to capture a tiny sample of bone marrow.47  The 
samples will then be sent to a lab where doctors will classify blood cells based on size, shape, 
and other molecular features, and hopefully determine the cause of high or low blood cell 
counts.48  Diagnosis of acute lymphoblastic leukemia is typically established by the presence of 
20% or more lymphoblasts in the bone marrow.43  The samples are originally assessed via 
morphology, to search for cancerous cells.  If the cells are found to be cancerous, the doctors will 
also be able to determine whether the cancer developed from B- or T-cell progenitors, thereby 
assisting in the potential treatment plan.  The samples may subsequently undergo examination to 
analyze potential chromosomal changes.49  Chromosomal analysis can include fluorescence in 
situ hybridization (FISH) to produce an image of the specific strands of DNA on each 
chromosome.49  Following the bone marrow biopsy, a physician may choose to order an imaging 
test such as a computerized tomography (CT) scan, X-ray, or ultrasound to determine if the 
cancer has spread to other parts of the body.48  Finally, at the time of diagnosis it is also standard 
for the physician to order a lumbar puncture with cerebrospinal fluid (CSF) analysis to evaluate 
for central nervous system involvement.43  CNS involvement in acute lymphoblastic leukemia is 
a serious clinical problem that requires CNS prophylaxis.  Typical chemotherapy treatments and 




intrathecal chemotherapy and/or cranial irradiation and high-dose systemic chemotherapy are 
typically necessary.50  For pediatric patients, however, cranial irradiation is highly 
unrecommended.  Intrathecal chemotherapy is refers to treatments given through a lumbar 
puncture to disperse the drug throughout the spinal cord and CSF.51  It is commonly administered 
to children who develop ALL in order to kill any cancer cells that may have spread to the brain 
and spinal cord, and prevent any others from rapidly dividing.  The treatment is typically given 
twice within the first month and then repeated much less frequently.51  All of these tests are 
typically administered to properly make an educated and informed diagnosis of leukemia. 
 
Treatment Plan 
Once the diagnosis is determined, the physician will then need to begin developing a 
treatment plan with the family.  While treatment of acute lymphoblastic leukemia has 
significantly increased over the years and led to increased survival rates in pediatric patients, the 
percentage of patients who relapse and become drug resistant still receive a very dismal 
prognosis.  Treatment of de novo patients regularly consists of 4 phases: induction, 
consolidation, intensification, and maintenance therapy.49  The goal of induction therapy is to rid 
the blood and surrounding tissues of as many leukemia cells as possible, preferably >99%.43,52  
Following induction, consolidation and intensification therapy are administered to kill any 
remaining leukemia cells in order to prevent relapse.49  Remaining cells may include those that 
migrate to the brain and spinal cord through the cerebrospinal fluid.  In rare cases, leukemia cells 
can develop within the bones of the skull, and can then travel to the cerebrospinal fluid thereby 
affecting the central nervous system.53  These cancerous cells are not usually affected by 




Eliminating radiation in children prevents the risk of secondary brain tumors and neuroendocrine 
failure, as well as other risks associated with the rapidly dividing cells children have.  However, 
CNS-directed chemotherapy can carry with it the risk of seizures, encephalopathy, and other 
neurocognitive toxicities, greatly affecting function and ability of the brain.53  The role and effect 
of the CNS in leukemia survival is not fully understood, and future studies in this area could be 
extremely beneficial in prevention of relapse ALL and treatment. 
Following intensification treatment, maintenance therapy is reached to prevent leukemic 
blasts from redeveloping.48  This third phase of treatment typically includes a combination of 
methotrexate and 6-mercaptopurine (6-MP).54  This stage usually lasts about two years, and CNS 
prophylaxis treatments are typically continued as well during this time. 
 
Resistance to Treatment 
 The resistance of some cancer cells, causing them to continue growing and dividing after 
treatment, leads to a devastating and dismal prognosis.  Effectiveness of treatment is determined 
by continued tests, such as those mentioned earlier.  A complete response shows that all of the 
cancer has disappeared and there is no further evidence of disease.55  With a partial response, the 
cancer may have shrunk by a percentage but is still evident.  If the cancer has neither grown nor 
shrunk it is referred to as stable disease, and if there is increased evidence of cancer it is defined 
as disease progression.55  If cancer cells that previously appeared to be responding to treatment 
begin to grow, it is defined as resistance.  There are several reasons the resistance may have 
occurred, including the appearance of clonal mutations as previously mentioned.  The 
chemotherapy, and other factors, can mutate the cells and cause them to become resistant to the 




treatment.55  Another possible mechanism is through gene amplification from a cancer cell that 
leads to production of a protein that comprises the effects of the anticancer drug.  Cancer cells 
may also use a molecule known as p-glycoprotein to pump the drug out of the cell as quickly as 
it is coming in.56  These mechanisms all lead to drug resistance, and typically a new drug must be 
administered.  In the case of resistance in relapsed cancers, the physician may recommend 
immunotherapy options or a hematopoietic stem cell transplant over further chemotherapy. 
 The road to recovery for a cancer patient can be a long battle, especially when resistance 
or relapse occurs, and secondary treatments become necessary.  The potential to decrease the 
need for continued treatment and drugs, such as those used for chemotherapy, through dual 
therapy treatments deserves to be investigated.  By introducing a combined treatment early on in 
the cancer fight, especially one which uses immunotherapy to encourage the patient’s immune 
system to do the fighting, it could decrease rates of cancer cell resistance.  Immunotherapy 
compels cancer cells to become more sensitive to chemotherapy treatment and therefore 













Research Design and Goals 
 In order to determine the efficacy of dual therapy treatment with Blinatumomab and 
chemotherapy, experiments will need to be performed on cancerous cells.  The purpose of the 
experiments will be to study both relapsed and primary cancer cell lines and to use those results 
to eventually proceed to clinical trials.  Promising results would show that the dual therapy 
treatment leads to more efficient control and minimization of relapsed cancer cell growth, as well 
as decreased rates of relapsed cancer cells from primary cell lines in comparison to monotherapy 
treatment with either Blinatumomab or the chemotherapy drug vincristine.  For these 
experiments, B-ALL cell lines should be used rather than murine models because they are better 
equipped to study the effects of drug targets on leukemia cells.  While a xenogeneic mouse 
model is incredibly efficient at engrafting human hematopoietic and leukemia cells, and is 
typically the preferred model for in vivo research of human-derived leukemia, it will not be 
sufficient for research with Blinatumomab.57,58  Xenogeneic mice are developed without a native 
immune system, which is key for their engraftment properties, but means that bispecific T-cell 
engagers (BiTE) such as Blinatumomab that are based on the immune system cannot be properly 
assessed.58  Therefore, the best model to be used to study the effects of combined therapy on 
relapsed leukemia cells would be relapsed leukemia cells from pediatric ALL patients.  Benefits 
of using patient-derived leukemia cell lines include an unlimited use of cell material, prolonged 
storage in liquid nitrogen and recoverability, long-lasting proliferation in culture, and more.59   
 After undergoing a procedure to separate out the white blood cells from red blood cells in 
samples of relapsed B-ALL cell lines, the collection of white blood cells will be tested for 
viability.  Viable cells are those that are living, and are therefore the only ones used for 




combined vincristine and Blinatumomab to determine cytotoxicity.59  Cell death is observed 
through breakdown of the cell membrane, condensation of nuclear material, and then 
fragmentation of the nucleus.60  Previously, cell cytotoxic activity was measured with a 
Chromium51 assay, but due to harmful effects of handling the radioactive compound, a new non-
radioactive and real-time cytotoxic assay was developed.61,62  Target-cell cytotoxicity is watched 
over time by imaging and live fluorescent target cells are measured in 96-well plates.61  These 
images can be picked up through a fluorescent reader such as ‘CytationTM 5’.62  By viewing the 
relapsed cell lines response to varying pressures, one would be able to sufficiently determine if 
dual therapy treatment would be worth projecting into clinical trials.  If the group of cultured 
cells that are treated with either Blinatumomab or vincristine alone experience a greater 
percentage of cell death than those treated with both agents, then the conclusion could be drawn 
that there is a reason the agents do not work synergistically when combined.  Therefore, further 
research would need to be done to examine the reasoning for the null results, and to thereby 
determine a renewed method to attack the cancerous cells.  However, if the results of the 
experiment showed increased apoptosis in cells treated with both vincristine and Blinatumomab, 
then the conclusion could be made that the dual therapy treatment does in fact show promise in 
fighting relapsed cells, and could potentially move forward into clinical trials. 
 While the number of patients that recover from primary acute lymphoblastic leukemia 
after typical treatment regimens is ever-increasing, the issue of relapse is still one leading to a 
dismal prognosis.  Therefore, it is vital to determine if Blinatumomab and chemotherapy dual 
treatment will be beneficial in decreasing rates of relapse, specifically in the pediatric population.  
In order to accomplish this, primary cell lines similar to those that would be used to test the 




cell lines would be used because then the potential for this combined therapy to not only increase 
survival rates for relapsed patients, but to decrease rates of relapse in this patient population 
could be studied.  Therefore, these cell lines would also be purified and cultured, and then treated 
in groups with either vincristine alone, Blinatumomab alone, or both agents.  Cytotoxicity would 
be measured again as a means to determine treatment efficacy.  There are many factors that have 
the potential to be studied within this experiment.  Malignant cells that beat the drugs and 
continue to divide after treatment is completed would show that the development of resistant 
cells may be just as likely as with common treatments currently being practiced and 
administered.   Furthermore, what if the length of time between treatment and cancer cell 
regrowth was significantly increased with this treatment compared to current treatments?  
Increasing the time between initial treatment and potential relapse means increasing the time a 
child can live cancer free.  Or perhaps this treatment leads to an even greater percentage of 
cancer cells becoming resistant to chemotherapy agents, and should therefore not be 
administered.  However, this is highly unlikely considering that the mechanism of Blinatumomab 
is to aid the patients’ immune system to target the cancerous cell, thereby making it more 
susceptible to the effects of the chemotherapy without highly pressuring it to become resistant. 
Therefore, if the results show that the combined treatment of vincristine and Blinatumomab leads 
to decreased relapse percentages in the cancer cell lines, increased treatment efficacy, or even an 
extended amount of time between primary and secondary cancer development, then with further 
studies this combination could be progressed to clinical trials.  Clinical trials would be able to 
study these processes within the human body, which is a much more complicated experimental 
field.  There are significantly more factors that can and most likely will affect the treatment of 




recorded.  Cancer cells are incredibly adaptive, especially within the human body, therefore it is 
crucial to study the effect treatment has on them in vivo. 
One of the issues being faced after treatment with Blinatumomab in acute lymphoblastic 
leukemia patients is that patients whose cancer cells develop clones that are CD19- will be 
unable to use Blinatumomab, which is known to target CD19 cell surface markers with one of its 
antibody arms.  Therefore, for the sake of a future potential population of patients, it is crucial to 
determine a different cell surface marker on cancerous B cells and to develop a different 
monoclonal antibody other than Blinatumomab to target them.  CD19- cells are extremely rare, 
which is why CD19 is the primary target for both acute lymphoblastic leukemia diagnosis and 
now immunotherapy treatment.63  However, with the development of CD19- leukemia cells that 
efficiently evade Blinatumomab, it may be necessary to use other known B-cell surface markers 
such as CD10, CD22, or CD24 that are strongly expressed on all stages of B-cells except plasma 
cells.63   
A monoclonal antibody is developed by a process of injecting a mouse with the antigen 
of interest, in this case CD3, and allowing its body to create antibodies for this antigen.  These 
antibodies are then collected and washed.  Following the washing stage, the cells are extracted 
from the liver and mixed with myeloma cells.  Myeloma cells are eternal cells that when merged 
with typical cells, will pass on their longevity.  This is key in order for more antibodies to be 
produced on a larger scale that fight the antigen of interest.  Following, the cells will placed on a 
HAT medium which will intentionally kill any of the unfused myeloma cells.  The cells that 
survive will screened by ELISA.  ELISA stands for enzyme-linked immuno-absorbent assay, and 
is a method used to bind antibodies to soluble antigen lining the wells of a 96-well microtiter 




their binding affinity to the antigen of choice to determine if they would be efficient and 
successful at marking cells for destruction.  The monoclonal antibodies that are produced from 
this experiment will then be stripped of their disulfide bonds which unite their two halves 
together, and then rejoined with each other in a fashion that creates an antibody with two 
different heads.  With these two heads the antibody is capable of targeting two different cells, 
one cancerous and the other normal.  This will place them in a juxtaposition for attack from other 
components in the body.  In order to determine if an antibody accurately binds to the desired 
antigen, an enzyme-linked secondary antibody specific for monoclonal immunoglobulins will 
then be used to bind to the mAb, which is then visualized by reaction with an appropriate 
enzyme that yields a colored product.64  This procedure can be seen in Figure 5.  The resulting 
antibodies can then be tested further by ELISA to determine binding affinity before placing them 
in cell cultures of leukemia cell clones that are CD19-.   
Assuming that the previous experiments were successful in increasing relapsed cancer 
cell death, as well as decreasing rates of relapsed cancer cells, if this experiment does not show 
efficient attacking and destruction of CD19- clones, then it can be concluded that there is a 
specific purpose behind targeting the CD19 receptor.  This could mean that CD19 is crucial in 
the identification of cancer cells by cells of the immune system.  Furthermore, if the experiment 
shows promising results of the cancer cell lines facing increased cell apoptosis, then it could 
prove that the newly generated antibody is capable of treating this specific population of patients.  
Furthermore, it would be interesting to continue watching the effects of this antibody on cell 
lines to see if new cancer cells develop that do not have the receptor that was targeted by these 
new antibodies.  Cancer cells are incredibly versatile and adaptable, and are constantly 





Acute lymphoblastic leukemia is the number one cancer diagnosed in pediatric patients.  
Being derived from leukocytes, leukemia can quickly take over the patients’ immune system, 
leading to the devasting side effects of the cancer.  Without a properly functioning immune 
system a patient is more susceptible to infection, along with other debilitating side effects such as 
anemia, fatigue, and heart disease.3  Despite significant increases in survival rates over the years, 
outcomes for patients who relapse are much more dismal.  Typical treatment protocol for ALL 
consists of induction, consolidation, intensification, and maintenance therapy.  Chemotherapy 
regimens also frequently contain the drugs vincristine and or doxorubicin, which have similar 
mechanisms of action in inhibiting the cancer cell cycle.  Secondary treatments include 
immunotherapy options such as monoclonal antibodies and CAR T-cell therapy, or a 
hematopoietic stem cell transplant.  Immunotherapy has shown the most significant benefit in 
patient outcomes and is therefore becoming the frontrunner in refractory cancer care.  
Monoclonal antibodies specifically, like Blinatumomab, have shown some of the greatest 
promise in fighting off cancer cells and cell clones that have become drug resistant at relapse.  
However, relapse remains to be one of the largest issues in treating cancer patients, and 
significantly decreases rates of survival, therefore methods to decrease rates of relapse are 
necessary.  Current treatments that are being used today have been shown to increase pressure in 
the cancer cell environment, leading to the cell developing resistant genes to the therapy that is 
being administered.  Therefore, a treatment that avoids this pressured environment would be 






Efficacy Over Current Treatments 
The use of Blinatumomab in fighting ALL has recently been approved by the FDA for 
administration, however the dual therapy treatment of acute lymphoblastic leukemia with 
Blinatumomab and chemotherapy such as vincristine is hypothesized to decrease rates of relapse 
in the pediatric population.  By combining the monoclonal antibody with the chemotherapy, the 
immune system will be more equipped to fight off the malignancy.  As previously mentioned, 
monoclonal antibodies work to enhance the patients’ own immune system at fighting off the 
cancer cells.  One arm of the antibody targets the CD19 receptor on leukemia cells, while the 
other arm targets the CD3 receptor on the functioning white blood cells.  Therefore, the white 
blood cells of the patient’s body are more adequately prepared to perform their cytotoxic effects 
on the cancer cell.  The added chemotherapy aids to slow down the cell cycle of the leukemia 
cells, increasing the efficacy of the Blinatumomab treatment.  This also removes the pressure that 
accompanies intensive chemotherapy, thereby leading to promising results and achievements for 
leukemia patients in comparison to the results of current treatments.  The intensive chemotherapy 
that is used in current treatments is incredibly harsh and non-specific, therefore leading to the 
debilitating side effects and potential for developed resistance.  A patient undergoing 
chemotherapy will be constrained by this treatment for 3-5 years.19  Children are typically not 
subjected to radiation due to its harmful effects on their rapidly dividing cells, thereby they 
require a more intensive or extended chemotherapy treatment regimen.  This means more years 
they are missing school, missing crucial childhood experiences and relationships, and missing 
the opportunity to just “be a kid” because of medical appointments and treatments.  This 
treatment has the potential to not only impact a child’s medical future and health, but also their 





Advantages to Proposed Dual Therapy Treatment 
Dual therapy treatment will be successful at both increasing survival rates of relapsed 
cancer patients, as well as decreasing rates of relapse in primary cancer patients.  With the above 
proposed experiments, it can be determined whether the combined treatment of vincristine and 
Blinatumomab will be more effective at treating secondary leukemia, preventing relapse from 
primary leukemia, and also effectively treating cancers without the CD19 receptor.  With the 
proposal of a procedure that will not only more effectively treat the cancer, but also decrease the 
risk of cancer cells being driven to resistance, the treatment protocol for a patient with acute 
lymphoblastic leukemia could be dramatically altered.  Rather than undergoing years of 
chemotherapy treatment and maintenance, the patient would be able to recruit the help of their 
own immune system rather than initially significantly depleting it, which allows for the strongest 
response against the cancer cells.  Furthermore, by decreasing the risk of relapse for the patient, 
it increases their quality of life and life expectancy.  The survival rate of patients who relapse is 
significantly decreased in comparison to patients diagnosed with the primary cancer.2   
Therefore, minimizing relapse rates by preventing resistant cells will increase the overall 
survival and overall cancer-free survival rates of a multitude of patients.  Along with increasing 
their lifespan, patients quality of life will also benefit from this proposed treatment.  They will no 
longer need to spend hours upon hours going to chemotherapy treatment and living in a 
maintenance stage, but will receive time back with the increased efficacy of treatment.  All in all, 
the benefits of the success of this proposed dual therapy treatment completely lie in the desire for 





Drawbacks and Future Research Design 
While there is incredible potential for many advantages to this combination treatment, 
there is also potential for problems to occur that will subsequently need to be addressed.  
Primarily, if there is no significant change in patient response and cancer cell cytotoxicity with 
the combined treatment in comparison to monotherapy treatments, then determining an alternate 
route, potentially with an alternate chemotherapy drug, will be necessary.  The relationship 
between the chemotherapy and Blinatumomab would need to be further examined to determine   
Furthermore, there may also be potential for harmful side effects from this treatment as there are 
with any new procedure.  While this is unexpected, due to the nature of the agents and the 
partnership between the monoclonal antibody and the patients cells, side effects are always 
present.  The majority of the side effects of Blinatumomab are mild and can be easily treated, 
and by decreasing the intensity of the chemotherapy many of those side effects should be curbed 
as well.  However, there are some side effects previously mentioned earlier such as cytokine 
release syndrome that will need to be strictly monitored.  Many of these will not be recognizable 
until continuation into clinical trials, which would occur after success in the proposed 
experiments within this paper.   
Furthermore, there is also the potential for increased cost of treatment in comparison to 
current treatments.  By combining chemotherapy with the monoclonal antibody, cost will 
initially be remarkably higher.  However, the potential for this treatment to decrease hospital 
visits, future chemotherapy treatments (including travel fees for the duration of consolidation and 
maintenance therapy), essentially outweighs the increased initial cost of the treatment.  
Considering that this treatment would also be applied to primary cancer patients in order to 




understand that this increased initial cost can provide relief from future costs and concerns that 
surface when a patient undergoes relapse. 
Overall, there is significant research being done in the field of oncology, which is 
necessary due to the ever-changing cancer cell and its numerous methods of expression.  
Studying pediatric acute lymphoblastic leukemia could provide hope to many families who are 
fighting this seemingly never-ending battle, or for those who are fighting relapse, the seemingly 
undefeatable battle.  There is still much work to be done, and many questions to be answered, but 
the progress that has been made in this field shows that each answer, however small, has purpose 














































































Figure 1. A representation of the formation of the Philadelphia 
chromosome from the fusion of the BCR gene and the AML gene.  Both 


















































Figure 2.  Various pathways of clonal evolution leading  to drug resistant 
phenotype of leukemia cells.  Note that approximately 94% of relapsed 



















































Figure 3.  The above diagram depicts the process by which CAR-T cells are 
engineered and re-administered to the patient.  The first step is to remove 
healthy leukocytes from the patient by leukapheresis/apheresis, then by 
introducing a viral vector into the DNA genome of the cells, they can present 
the CAR.  Cells are then expanded and purified, then tested for quality and 


















































Figure 4.  The above image depicts the mechanism through which Blinatumomab binds to CD3 



















































Figure 5.  The above graphs show the comparison between patients who only received 
chemotherapy and those who received chemotherapy and the monoclonal antibody rituximab.  
Graph A depicts the rate of event-free survival, graph B shows progression-free survival, and 
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